Jasper Therapeutics Inc Stock Price, News & Analysis

Jasper Therapeutics (Nasdaq: JSPR) presented preclinical data on briquilimab at the 2024 EHA Hybrid Congress in Madrid. This study focused on the impact of briquilimab, a novel antibody therapy targeting c-Kit (CD117), on hematopoietic stem cells (HSCs). The findings indicate that while briquilimab blocks SCF/c-Kit signaling, it does not cause apoptosis in healthy HSCs. Instead, it promotes HSC differentiation into CD34- cells with higher c-Kit expression but without increased CD38 expression. These results support briquilimab's safety profile for treating mast cell-driven diseases like chronic urticaria and asthma.

Jasper Therapeutics will present data on briquilimab at the EAACI Congress 2024 in Valencia, Spain from May 31 to June 3. Briquilimab, a novel antibody targeting c-Kit (CD117), aims to treat mast cell-driven diseases like asthma, chronic spontaneous urticaria (CSU), and chronic inducible urticaria (CIndU). Key findings include briquilimab's ability to deplete mast cells and improve lung function in asthma models, as well as reduce dermal mast cells and inflammatory leukocytes in atopic dermatitis (AD) models. A healthy volunteer study showed briquilimab is well-tolerated, with promising pharmacokinetic and pharmacodynamic profiles. The data supports ongoing BEACON and SPOTLIGHT trials in CSU and CIndU. Jasper plans to begin a Phase 1b/2a trial in asthma later in 2024.

Jasper Therapeutics (Nasdaq: JSPR) will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 4:00pm EDT. The biotechnology company, focused on developing briquilimab for diseases like chronic spontaneous urticaria, chronic inducible urticaria, and asthma, will provide a live webcast of the presentation on their Investor Relations website. The presentation will also be archived for 30 days.

Jasper Therapeutics (Nasdaq: JSPR), a biotechnology company developing briquilimab for mast cell-driven diseases, announced its Q1 2024 financial results and corporate updates.

Key progress includes enrollment in Phase 1b/2a BEACON and SPOTLIGHT studies for chronic urticarias, with initial data expected in Q3 and H2 2024.

Jasper is also advancing briquilimab for asthma, starting enrollment in Q4 2024.

Financially, Jasper reported a net loss of $13.7 million, with cash reserves of $118.5 million, extending its runway through Q3 2025 after a $50 million stock offering in February 2024.

Other developments include positive data on briquilimab for CGD and MDS, and the issuance of inducement stock options to new employees.

Jasper Therapeutics, Inc. (Nasdaq: JSPR) announced the initiation of a Phase 1b/2a study evaluating briquilimab in asthma patients in Q4 2024. Briquilimab targets mast cell-driven diseases like chronic spontaneous urticaria and chronic inducible urticaria. The company presented promising preclinical data at the recent AAAAI annual meeting, demonstrating the depletion of mast cells in the airways and prevention of allergen-induced asthmatic responses. Jasper plans to host a KOL webinar on May 20, 2024, featuring Professor Joshua Boyce to discuss the potential of briquilimab in asthma.

Jasper Therapeutics, Inc. (Nasdaq: JSPR) will present at upcoming investor conferences in May to discuss the development of briquilimab, a novel antibody therapy addressing mast cell driven diseases. The company's management will participate in panel discussions at Capital One Securities Biotech/Biopharma Disruptors Event and in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference.